Dr. Giampaolo Trivellin’s research activity concerns the study of genetic defects causing tumors of the pituitary gland, in particular those leading to gigantism in children and acromegaly in adults. This line of study began in 2008 during his PhD in Padova in the laboratory of Prof. Carla Scaroni and continued during his first post-doctoral experience in the laboratory of Prof. Marta Korbonits at the Queen Mary University of London, in the United Kingdom. Dr. Trivellin then moved to the laboratory of Dr. Constantine Stratakis at the National Institutes of Health, in the United States. In his lab, in 2014, Dr. Trivellin identified a new gene, an orphan receptor named GPR101, involved in the most extreme cases of infantile-onset pituitary gigantism. Subsequently, his work was focused on the identification of GPR101 ligands and on understanding how the receptor regulates children’s growth. For these studies he employed transgenic zebrafish models and cell lines that he developed.
In 2020, Dr. Trivellin started a junior investigatorship (Marie Curie fellowship) at the Humanitas Research Hospital. In 2021, he was awarded a Telethon grant to continue his line of research. His current research interest is the functional characterization of GPR101 by identifying the epigenetic mechanisms controlling its expression in normal and tumor pituitary cells and by quantifying the intracellular effects elicited by newly discovered GPR101 inhibitors. In December 2022, Dr. Trivellin became Assistant Professor at Humanitas University.